Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
20%
Ph phase_3
3
60%
Ph phase_1
1
20%

Phase Distribution

1

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
3(60.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 21 (20.0%)
Phase 33 (60.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_2

Efficacy and Safety of SR46349B in Patients With Sleep Disorders in Fibromyalgia

NCT00313885
completedphase_1

Single Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluation of Eplivanserin in Children With Insomnia

NCT00913614
completedphase_3

Comparison of Eplivanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties

NCT00679900
completedphase_3

Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia Followed by Optional Extension up to 1 Year

NCT00253903
completedphase_3

Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia

NCT00308503

Clinical Trials (5)

Showing 5 of 5 trials
NCT00313885Phase 2

Efficacy and Safety of SR46349B in Patients With Sleep Disorders in Fibromyalgia

Completed
NCT00913614Phase 1

Single Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluation of Eplivanserin in Children With Insomnia

Completed
NCT00679900Phase 3

Comparison of Eplivanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties

Completed
NCT00253903Phase 3

Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia Followed by Optional Extension up to 1 Year

Completed
NCT00308503Phase 3

Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5